Other potentially treatable conditions with PDE10A inhibitors include schizophrenia, Huntington’s disease, L-dopa-induced dyskinesia in Parkinson’s disease, and childhood-onset fluency disorder. This evidence concerns the gene PDE10A and drug-induced dyskinesia.